Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (the Company) (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA. Accordingly, the FDA is not able to issue an action letter in time to meet the previously issued Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024, and their review remains ongoing. The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.
Related news for (LQDA)
- Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
- U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
- Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
- District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia